Sign in

You're signed outSign in or to get full access.

Jonathan Hunt

Chief Accounting Officer at Perspective Therapeutics
Executive

About Jonathan Hunt

Jonathan Hunt is Chief Accounting Officer and Principal Accounting Officer of CATX since August 16, 2024; he served as Chief Financial Officer from December 3, 2018 to January 6, 2025 and previously from 2006 to 2009 . He is 58 and holds a BS in Accountancy and a Master of Accountancy from Brigham Young University . Prior roles include CFO at Vivid Learning Systems (2009–2018) where he led a turnaround and sale, and Assistant Corporate Controller at Hypercom Corporation (2005–2006) . Company performance context: cumulative TSR value per $100 initial investment was $39.88 in 2024 (down from $50.00 in 2023), and GAAP net losses were $79.3 million in 2024 and $46.5 million in 2023 .

Past Roles

OrganizationRoleYearsStrategic Impact
CATX (Perspective Therapeutics)Chief Financial Officer2018–2025Served as CFO from Dec 3, 2018 to Jan 6, 2025; Co-Principal Financial Officer Feb 12, 2019–Jan 6, 2025 .
CATX (Isoray, Inc.)Chief Financial Officer2006–2009CFO of the Company in earlier tenure .
CATXChief Accounting Officer, Principal Accounting Officer2024–presentAppointed CAO Aug 16, 2024; currently Principal Accounting Officer .

External Roles

OrganizationRoleYearsStrategic Impact
Vivid Learning SystemsChief Financial Officer2009–2018Led turnaround, revenue growth, policy/process changes culminating in successful sale of the business .
Hypercom CorporationAssistant Corporate Controller2005–2006Financial reporting and controls at global payments hardware provider .

Fixed Compensation

MetricFY 2023FY 2024
Base Salary ($)$389,154 $447,365
Target Bonus % of Salary40% for NEOs (Hunt)
Sign‑on Bonus ($)$30,000 (paid per 2023 employment agreement)
All Other Compensation ($)$353,200 (includes $340,000 change‑in‑control payments and $13,200 401(k) match) $13,800 (401(k) match)

Performance Compensation

Annual Cash Incentive

MetricFY 2023FY 2024
Bonus Opportunity (% of Salary)40% of base salary
Payout (% of Salary)33% of 2024 base salary
Payout ($)$172,000 $150,000
BasisCorporate objectives; determined by Compensation Committee, paid following year Corporate objectives; determined by Compensation Committee, paid following year

Option Awards (Grant‑level Detail)

Grant Date# OptionsExercise Price ($)ExpirationVesting
Jun 20, 2024100,000 10.65 06/20/2034 1/48 monthly starting Jul 20, 2024
Dec 12, 2023124,877 (62,439 exercisable; 62,438 unexercisable as of 12/31/24) 2.40 12/12/2033 25% at grant; 25% annually on Dec 12, 2024/2025/2026
Jul 21, 202247,499 (fully exercisable by 2/3/23 due to CoC) 3.30 07/21/2032 25% at grant; remainder vested at merger (CoC)
Jul 01, 202132,000 (remainder vested at 2/3/23 CoC) 7.90 07/01/2031 25% annually; remainder vested at merger (CoC)
Jun 23, 202015,000 (remainder vested at 2/3/23 CoC) 6.10 06/23/2030 25% annually; remainder vested at merger (CoC)
Jun 18, 201915,000 (fully exercisable as of 6/18/22) 4.30 06/18/2029 Fully vested by 2022
Dec 03, 201815,000 (fully exercisable as of 12/03/21) 4.30 12/03/2028 Fully vested by 2021

Equity Program Design

  • Options granted under the 2020 Equity Incentive Plan; 10‑year term; exercise price equal to closing price at grant; vesting schedule changed in June 2024 to monthly vesting for existing executives (48 monthly installments) .
  • No option repricing or material modifications in 2023–2024 .

Equity Ownership & Alignment

As ofCommon Shares OwnedOptions Exercisable within 60 DaysWarrantsPercent of Class
Apr 2, 202548,800 212,979 3,365 <1%
Outstanding Equity Awards (12/31/2024)Exercisable (#)Unexercisable (#)Notes
Jun 20, 2024 Grant12,500 87,500 1/48 monthly from 7/20/24
Dec 12, 2023 Grant62,439 62,438 25% annual tranches
Prior Grants (2018–2022)124,999 total (47,499; 32,000; 15,000; 15,000; 15,000) Mostly fully exercisable; several accelerated at 2/3/23 CoC
  • Anti‑hedging and pledging: Company policy prohibits hedging, short sales, derivative trading, and pledging/margin accounts for directors, officers, employees, and related parties .
  • Ownership guidelines: Not disclosed.

Employment Terms

TermProvision
Current Agreement Effective DateJune 16, 2023 (at‑will) .
Base Salary (Agreement reference)Annual salary set by Compensation Committee; not decreased without consent (except broad reductions) .
Bonus EligibilityQuarterly and annual discretionary bonus based on Compensation Committee‑set metrics .
Severance (termination without cause or resignation for good reason)12 months’ base salary; pro‑rated quarterly/annual bonuses; COBRA premiums up to 12 months; accrued wages/approved expenses .
Change‑of‑Control (if not retained)Same severance as above; plus accrued items .
Change‑of‑Control (regardless of retention)Additional 12 months’ salary paid per regular payroll practices .
Equity Acceleration on CoCAll outstanding unvested equity awards vest and become immediately exercisable/unrestricted at executive’s option .
Restrictive Covenants1‑year non‑compete and non‑solicit; standard confidentiality .
Clawback PolicyBoard‑adopted recoupment for executive performance‑based compensation upon required restatement per SEC/NYSE rules .

Investment Implications

  • Alignment: Hunt’s equity exposure comprises options rather than RSUs/PSUs; combined with the Company’s anti‑hedging/pledging policy, incentives align with long‑term share appreciation and compliance frameworks .
  • Vesting cadence and potential selling pressure: The June 20, 2024 grant vests monthly over 48 months, creating a steady stream of newly vested options that may be exercised/sold; monitor Form 4s around monthly vest dates for potential trading signals .
  • Severance/CoC economics: The agreement includes single‑trigger elements—12 months’ salary payable upon change‑of‑control regardless of retention, and optional full equity acceleration—reducing retention risk for the executive but increasing potential dilution/alignment questions for investors in sale scenarios .
  • Pay‑for‑performance: 2024 cash bonus paid at 33% of salary vs 40% target (corporate objectives basis), indicating partial attainment or Committee discretion; options valued at $884,733 in 2024 dominate compensation mix, reinforcing long‑term equity orientation .
  • Ownership: Beneficial ownership is <1% of common stock with 212,979 options exercisable within 60 days as of April 2, 2025; small direct share ownership suggests incentive dependence on options and realized value timing .
  • Track record: Prior turnaround and successful exit at Vivid Learning Systems supports execution credibility in finance and operations; current context includes declining TSR and larger GAAP net loss in 2024, underscoring execution risk in achieving milestones that drive equity value .